Logo

American Heart Association

  17
  0


Final ID: MP720

Impact of Damaging Genetic Variants on Right Ventricular Function in Tetralogy of Fallot

Abstract Body (Do not enter title and authors here): Background: Right ventricular (RV) dysfunction is an important determinant of outcomes in many forms of CHD. However, clinical and imaging biomarkers explain only 25% of the variability in long-term outcomes in patients with repaired tetralogy of Fallot (rTOF). The contribution of genetic factors to RV dysfunction in rTOF is a knowledge gap.

Hypothesis: Genetic factors contribute to variation in RV function in patients with rTOF.

Methods: We studied the relationship of rare damaging genetic variants (RDV) and RV function, assessed by cardiac MRI in a cohort of 223 rTOF patients with genome or exome sequencing, recruited under the auspices of the Pediatric Cardiac Genomics Consortium at Boston Children’s Hospital. We characterized demographics, genotypes, clinical and postoperative variables, and cardiac MRI measurements. Rare variants (gnomAD allele frequency <10-4) were considered damaging if predicted to be loss-of-function (nonsense, frameshift, or read-through), missense (REVEL score >0.5), or splice altering (SpliceAI delta score >0.8). Association was determined by comparing the proportion of participants with RV dysfunction (RV ejection fraction <45%) and RDV in 70 genes associated with pediatric onset cardiomyopathy, as reported in ClinVar. We performed multivariable logistic regression to adjust for independent predictors of RV dysfunction.

Results: Patients with rTOF and RV dysfunction were older at MRI (15.3 years vs. 12.6 years, p=0.01), and more likely to be male (71% vs. 49%, p=0.002), have a history of arrhythmia (26% vs. 11%, p=0.008), or repaired prior to 1985 (17% vs 6%, p = 0.01). 22q11 deletion syndrome was not associated with RV dysfunction. Heterozygous RDV in genes associated with pediatric cardiomyopathy were more common in patients with RV dysfunction (11% vs. 1%; OR 8.63, p =0.007). In a multivariable model (C statistic = 0.71), presence of a pediatric cardiomyopathy variant remained associated with RV dysfunction (OR 1.44, p=0.01).

Conclusions: RDV in genes associated with pediatric cardiomyopathy are associated with RV dysfunction in patients with rTOF. These genes would not be expected to be causal for CHD but instead modify myocardial function. While future larger multicenter studies should validate these findings, these results suggest that pediatric cardiomyopathy variants may affect outcomes, improve risk-stratification, and provide more precise personalized therapies for CHD.
  • Bowen, Caitlin  ( Boston Children's Hospital , Boston , Massachusetts , United States )
  • Roberts, Amy  ( Boston Children's Hospital , Boston , Massachusetts , United States )
  • Seidman, Jonathan  ( Harvard Medical School , Boston , Massachusetts , United States )
  • Tristani-firouzi, Martin  ( Health Sciences Center , Salt Lake City , Utah , United States )
  • Wagner, Michael  ( Cincinnati Childrens Hospital , Cincinnati , Ohio , United States )
  • Seidman, Christine  ( MGB and Harvard Medical School , Boston , Massachusetts , United States )
  • Newburger, Jane  ( Boston Children's Hospital , Boston , Massachusetts , United States )
  • Geva, Tal  ( Boston Children's Hospital , Boston , Massachusetts , United States )
  • Morton, Sarah  ( Boston Children's Hospital , Boston , Massachusetts , United States )
  • Avillach, Paul  ( Boston Children's Hospital , Boston , Massachusetts , United States )
  • Brueckner, Martina  ( Yale University School of Medicine , New Haven , Connecticut , United States )
  • Chung, Wendy  ( Boston Children's Hospital , Boston , Massachusetts , United States )
  • Cnota, James  ( Cincinnati Childrens Hospital , Cincinnati , Ohio , United States )
  • Gelb, Bruce  ( ICAHN SCHOOL MEDICINE , New York , New York , United States )
  • Lewis, Matthew  ( Columbia University , Larchmont , New York , United States )
  • Liu, Cong  ( Boston Children's Hospital , Boston , Massachusetts , United States )
  • Author Disclosures:
    Caitlin Bowen: DO NOT have relevant financial relationships | Amy Roberts: No Answer | Jonathan Seidman: DO have relevant financial relationships ; Research Funding (PI or named investigator):Eulamin:Expected (by end of conference) ; Consultant:Cora:Expected (by end of conference) | Martin Tristani-Firouzi: No Answer | Michael Wagner: DO NOT have relevant financial relationships | Christine Seidman: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):Merck, Board of Directors:Active (exists now) ; Advisor:Tenaya:Active (exists now) ; Advisor:Maze:Past (completed) | Jane Newburger: DO have relevant financial relationships ; Research Funding (PI or named investigator):PFizer:Active (exists now) ; Other (please indicate in the box next to the company name):Bristol-Myer-Squibb- DSMB Co-Chair for trial on pediatric mavacamten:Active (exists now) ; Research Funding (PI or named investigator):Bristol-Myer-Squibb- Chair, Independent Events Adjudication Committee for Pediatric Apixaban trials:Past (completed) ; Research Funding (PI or named investigator):Pfizer- Chair, Independent Events Adjudication Committee for pediatric apixaban trials:Past (completed) | Tal Geva: DO NOT have relevant financial relationships | Sarah Morton: DO NOT have relevant financial relationships | Paul Avillach: No Answer | Martina Brueckner: No Answer | Wendy Chung: DO NOT have relevant financial relationships | James Cnota: DO NOT have relevant financial relationships | Bruce Gelb: DO have relevant financial relationships ; Consultant:BioMarin:Active (exists now) ; Royalties/Patent Beneficiary:Correlegan:Active (exists now) ; Royalties/Patent Beneficiary:Prevention Genetics:Active (exists now) ; Royalties/Patent Beneficiary:LabCorp:Active (exists now) ; Royalties/Patent Beneficiary:GeneDx:Active (exists now) ; Consultant:Think Bioscience:Active (exists now) | Matthew Lewis: No Answer | Cong Liu: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Genetic and Molecular Mechanisms in Congenital Heart Disease: From Pathogenesis to Targeted Therapies

Saturday, 11/08/2025 , 12:15PM - 01:30PM

Moderated Digital Poster Session

More abstracts on this topic:
A new genetic model organism for primate-specific cardiac function and disease

Chang Stephen, Albertelli Megan, Quertermous Thomas, Wright Patricia, Terrien Jeremy, Aujard Fabienne, Wu Joseph, Krasnow Mark, Karanewsky Caitlin, Pendleton Jozeph, Ren Lu, Anzeraey Aude, Froelicher Victor, Liang David, Razafindrakoto Andriamahery, Ravelonjanahary Noeline

A Case of Concomitant Wild-Type Transthyretin and Systemic Light Chain Amyloidosis Involving Separate Organs

Chiu Leonard, Afrough Aimaz, Nadeem Urooba, Jebakumar Deborah, Grodin Justin

More abstracts from these authors:
Dysregulation of DSCAM and Sclerostin Signaling in Down Syndrome Associated Congenital Heart Disease and Other Phenotypes

Tang Vi, Zhang Qi, Morton Sarah, Mckean David, Narayan Priyanka, Layton Olivia, Sharma Ananya, Seidman Jonathan, Seidman Christine

Thrombophilia Variants Do Not Predict Thrombotic Events in Congenital Heart Disease: Insights from the Pediatric Cardiac Genomics Consortium

Ladha Feria, Roberts Amy, Seidman Christine, Tristani-firouzi Martin, Wagner Michael, Morton Sarah, Newburger Jane, Vanderpluym Christina, Avillach Paul, Brueckner Martina, Chung Wendy, Cnota James, Gelb Bruce, Lewis Matthew, Liu Cong

You have to be authorized to contact abstract author. Please, Login
Not Available